WO2008142569A2 - Topical compositions containing magaldrate - Google Patents

Topical compositions containing magaldrate Download PDF

Info

Publication number
WO2008142569A2
WO2008142569A2 PCT/IB2008/002047 IB2008002047W WO2008142569A2 WO 2008142569 A2 WO2008142569 A2 WO 2008142569A2 IB 2008002047 W IB2008002047 W IB 2008002047W WO 2008142569 A2 WO2008142569 A2 WO 2008142569A2
Authority
WO
WIPO (PCT)
Prior art keywords
magaldrate
ulcers
vitamin
compounds
lesions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2008/002047
Other languages
French (fr)
Other versions
WO2008142569A3 (en
Inventor
Pier Luigi Guasti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIFASS SA
Original Assignee
DIFASS SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIFASS SA filed Critical DIFASS SA
Priority to US12/593,299 priority Critical patent/US8617618B2/en
Priority to EP08789004.2A priority patent/EP2139451B1/en
Publication of WO2008142569A2 publication Critical patent/WO2008142569A2/en
Publication of WO2008142569A3 publication Critical patent/WO2008142569A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • compositions containing magaldrate which are useful to regenerate skin tissue in the treatment of some diseases of the skin and the nasal, vaginal and rectal mucous membranes.
  • the compositions according to the invention are useful in the treatment and prophylaxis of irritative and inflammatory states of the skin, and as wound-healing agents.
  • Magaldrate is a substance deriving from the combination of aluminium hydroxide and magnesium hydroxide, corresponding to the formula AI5 Mg-m (OH)3i (SO-O2 x H2O, with a molecular weight of approx. 1097. Magaldrate is described as a white, crystalline powder insoluble in water and alcohol; the dry base contains 34-46% magnesium oxide, 21-30% aluminium oxide and 13.3-17.5% sulphur trioxide.
  • Magaldrate is described in the official monographs of the European Pharmacopoeia (5th edition) and the US Pharmacopoeia (USP 29th edition).
  • magaldrate is known and widely used as an ulcer treatment drug, as it possesses marked activity as an antacid buffer. It has been demonstrated that magaldrate has a rapid, persistent ability to maintain the gastric pH in a range of 3-5, and possesses cytoprotective activity. Its efficacy in promoting the healing of gastric and duodenal ulcers is well documented; basically, magaldrate neutralises the gastric acids by inhibiting the proteolytic activity of pepsin. The most recent studies demonstrate that antacids play a more important therapeutic role than as mere palliatives in the treatment of gastric ulcers. Another considerable advantage in the use of magaldrate is its excellent tolerability, demonstrated during its use in gastric disorders: in toxicity tests relating to single and repeated oral doses, it proved almost non-toxic.
  • Antacid compounds which exert a neutralising effect (US2003157195) or a buffer effect (US 5362488 and US 5436007) on damaged skin have been described.
  • Magaldrate not only acts as a pH buffer but possesses cytoprotective activity; published studies demonstrate that this activity is due to protection of the mucosa from lipid peroxidation and the ability to stimulate endogenous prostaglandin (PGE2) synthesis (Indian J. Physiol Pharmacol. 2000 JuI; 44(3): 350-4 Arzneistoffforschung. 1989 JuI; 39(7): 786-9); Hepato-Gastroenterology 1998; 45:2443-2446).
  • Magaldrate creates an environment which promotes epithelial repair and cell regrowth.
  • magaldrate intake is not followed by any significant absorption of aluminium or magnesium, and does not alter the calcium or phosphorus metabolism.
  • Magaldrate only performs its action at gastrointestinal level, and has no systemic pharmacological effects or toxicity.
  • magaldrate The therapeutic properties of magaldrate are not the same as those of other compounds based on aluminium and magnesium oxides, but derive from the specific ratio between the components, which is crucial in determining the buffer properties of the compound.
  • topical magaldrate exerts a regenerating and anti- inflammatory action on the damaged epidermis, e.g. in the case of ulcers, venous ulcers, superficial ulcers, wounds, burns, eczema, rashes, psoriasis, ulcers, venous ulcers, superficial ulcers, wounds, burns, eczema, rashes, psoriasis, cutaneous lesions, diabetic lesions, traumatic lesions, surgical wounds, abrasions, dermatitis, macerations, stoma skin complications, inflammatory and/or infective skin disorders.
  • the present invention therefore relates to topical compositions of magaldrate suitable for application to the skin and the nasal, vaginal and rectal mucous membranes.
  • suitable carriers include native collagen, particularly native collagen type i, ii and iii from any source such as equine, bovine, porcine or aviarian collagen, vegetal collagen, hydrolyzed collagen, synthetic collagen, collagen may be in lyophilised or gel form, hyaluronic acid or derivatives thereof such as sodium hyaluronate, in crystalline form or in solution, as well as alginates may be conveniently used as carriers for magaldrate.
  • native collagen particularly native collagen type i, ii and iii from any source such as equine, bovine, porcine or aviarian collagen
  • vegetal collagen hydrolyzed collagen
  • synthetic collagen may be in lyophilised or gel form
  • hyaluronic acid or derivatives thereof such as sodium hyaluronate
  • crystalline form or in solution as well as alginates may be conveniently used as carriers for magaldrate.
  • compositions according to the invention can be formulated in any form convenient for topical use, in particular cream, vaginal/rectal cream, lotion, dusting powder, gel, creamgel, foams, powders for spray doser, patches, gauzes, hydrofibers, hydrocolloids, hydrogel, alginates, sponges, tissues/tablets, adhesive or non adhesive-films.
  • Examples of preferred combinations of the above mentioned carriers and/or ingredients include: Magaldrate + collagen;
  • Magaldrate is present in the formulations in concentrations of between
  • magaldrate can be present in percentages of between 0.5% and 50% by weight, and preferably between 1 % and 15%.
  • magaldrate can be supplemented by adding adjuvants, synergic and/or complementary substances such as vitamin E (tocopherols), vitamin A (retinol), vitamin C, alpha lipoic, camosine, zinc compounds, zinc oxide, cysteine, flavonoids, carotenoids, phytosterols, aloe, ozonized oil, alginates, amikacin or other antibiotics/anti-septics, silver compounds (e.g.
  • the product can be formulated as a vaginal pessary, ointment, suspension or cream. These preparations can be manufactured by known techniques, using conventional excipients.
  • a fatty base for example, a fatty base, one or more emulsifying agents, an aqueous phase and one or more antimicrobial agents are generally used for the cream formulation.
  • the following ingredients are used: - Fatty substance amounting to between 5% and 70% by weight, and preferably between 10% and 40%.
  • Emulsifying agent amounting to between 0% and 20% by weight, and preferably between 0.5% and 10%.
  • - Water amounting to between 10% and 90% by weight, and preferably between 40% and 80%.
  • Thickening agent amounting to between 0% and 6% by weight, and preferably between 0% and 2%.
  • Fatty base means a substance that is liquid or solid at ambient temperature which may be an aliphatic fatty acid ester, an aromatic acid ester, a triglyceride, a long-chain aliphatic alcohol, vaseline, lanolin or liquid paraffin.
  • the fatty substance used is not limited to a particular quantity but can vary, depending on the characteristics of the cream.
  • Anionic, cationic, non-ionic or amphoteric surfactants can be used as emulsifying agents.
  • the non-ionic type is generally preferable because it is less irritating to the damaged skin; it may be the oxyethylenated, polyhydroxide or polymer type.
  • the oxyethylenated type can be a derivative between an alcohol with a high molecular weight and a fatty acid, or an oxyethylenated derivative of a alkyl-phenol, an aliphatic amine, a polyvalent alcohol, etc.
  • the polyhydroxide type can include, for example, fatty acid monoesters of glycerin, a sorbitan ester of fatty acid, an amide between a fatty acid and ethanolamine, a monoester between a fatty acid and polyoxypropylene, a monoester between a fatty acid and polyoxyethylene glycerin, and so on.
  • Said emulsifying agents can be used separately or mixed together.
  • the emulsifying agent used is not restricted to a particular quantity, but can vary according to the desired characteristics of the end product. Said quantity is usually between 1 % and 20%, and preferably between 3% and 15%, by weight.
  • excipients are used for the lotion formulation; they basically comprise a fatty base, one or more emulsifying agents, an aqueous phase, and one or more antimicrobial agents.
  • the following ingredients are used:
  • a liquid fatty substance amounting to between 1% and 40% by weight, and preferably between 5% and 20%.
  • Emulsifying agent amounting to between 0% and 20% by weight, and preferably between 0.5% and 5%.
  • - Water amounting to between 0% and 90% by weight, and preferably between 50% and 80%.
  • a thickening agent amounting to between 0% and 6% by weight, and preferably between 0.05% and 2%.
  • the dusting powder formulation is particularly indicated in cases involving formation of exudates, which are absorbed and agglomerated by the product, thus creating an effective barrier against external agents which often cause further complications.
  • the excipients act as diluents, promote the flowability of the powder mixture, and prevent it from caking.
  • CETOMACROGOL 1000 3.O g ISOPROPYL MYRISTATE 2.5 g
  • Dusting powder based on 5% magaldrate and 2% zinc oxide
  • the preparation involves simply mixing the ingredients. However, this operation must be conducted under conditions that guarantee the sterility of the product.
  • the lipohilic phase is heated to 70-75 0 C 1 stirring with a mixer to obtain melting/homegeneization of the components. Part of water is added with stirring, keeping the above temperature. Temperature is then lowered to T ⁇ 40°C, the hydrophilic components are dissolved/dispersed the powders in water, then added with stirring to complete homogeization. Finally pH is adjusted with lactic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.

Description

TOPICAL COMPOSITIONS CONTAINING MAGALDRATE
This invention relates to topical compositions containing magaldrate which are useful to regenerate skin tissue in the treatment of some diseases of the skin and the nasal, vaginal and rectal mucous membranes. In particular, the compositions according to the invention are useful in the treatment and prophylaxis of irritative and inflammatory states of the skin, and as wound-healing agents.
BACKGROUND TO THE INVENTION
Magaldrate is a substance deriving from the combination of aluminium hydroxide and magnesium hydroxide, corresponding to the formula AI5 Mg-m (OH)3i (SO-O2 x H2O, with a molecular weight of approx. 1097. Magaldrate is described as a white, crystalline powder insoluble in water and alcohol; the dry base contains 34-46% magnesium oxide, 21-30% aluminium oxide and 13.3-17.5% sulphur trioxide.
Magaldrate is described in the official monographs of the European Pharmacopoeia (5th edition) and the US Pharmacopoeia (USP 29th edition).
Magaldrate is known and widely used as an ulcer treatment drug, as it possesses marked activity as an antacid buffer. It has been demonstrated that magaldrate has a rapid, persistent ability to maintain the gastric pH in a range of 3-5, and possesses cytoprotective activity. Its efficacy in promoting the healing of gastric and duodenal ulcers is well documented; basically, magaldrate neutralises the gastric acids by inhibiting the proteolytic activity of pepsin. The most recent studies demonstrate that antacids play a more important therapeutic role than as mere palliatives in the treatment of gastric ulcers. Another considerable advantage in the use of magaldrate is its excellent tolerability, demonstrated during its use in gastric disorders: in toxicity tests relating to single and repeated oral doses, it proved almost non-toxic.
Antacid compounds which exert a neutralising effect (US2003157195) or a buffer effect (US 5362488 and US 5436007) on damaged skin have been described. Magaldrate not only acts as a pH buffer but possesses cytoprotective activity; published studies demonstrate that this activity is due to protection of the mucosa from lipid peroxidation and the ability to stimulate endogenous prostaglandin (PGE2) synthesis (Indian J. Physiol Pharmacol. 2000 JuI; 44(3): 350-4 Arzneimittelforschung. 1989 JuI; 39(7): 786-9); Hepato-Gastroenterology 1998; 45:2443-2446).
Evidence in favour of the cytoprotective activity of magaldrate has been obtained in laboratory animals and in tests on humans; it also possesses a marked ability to adsorb lysolecithin and bile acids, and consequently to prevent the epithelial damage to the gastric mucosa caused by those components.
Basically, Magaldrate creates an environment which promotes epithelial repair and cell regrowth.
Studies conducted on humans demonstrate that oral magaldrate intake is not followed by any significant absorption of aluminium or magnesium, and does not alter the calcium or phosphorus metabolism. Magaldrate only performs its action at gastrointestinal level, and has no systemic pharmacological effects or toxicity.
The therapeutic properties of magaldrate are not the same as those of other compounds based on aluminium and magnesium oxides, but derive from the specific ratio between the components, which is crucial in determining the buffer properties of the compound. In this respect, see the publication in J Pharmacol Exp Ther. 1992 Dec; 263(3): 1206-11 which demonstrates that compounds with different Al/Mg ratios have similar activities in vitro but different activities in vivo, where the aluminium ions tend to form complexes.
DESCRIPTION OF THE INVENTION
It has now been found that topical magaldrate exerts a regenerating and anti- inflammatory action on the damaged epidermis, e.g. in the case of ulcers, venous ulcers, superficial ulcers, wounds, burns, eczema, rashes, psoriasis, ulcers, venous ulcers, superficial ulcers, wounds, burns, eczema, rashes, psoriasis, cutaneous lesions, diabetic lesions, traumatic lesions, surgical wounds, abrasions, dermatitis, macerations, stoma skin complications, inflammatory and/or infective skin disorders.
The present invention therefore relates to topical compositions of magaldrate suitable for application to the skin and the nasal, vaginal and rectal mucous membranes.
Examples of suitable carriers include native collagen, particularly native collagen type i, ii and iii from any source such as equine, bovine, porcine or aviarian collagen, vegetal collagen, hydrolyzed collagen, synthetic collagen, collagen may be in lyophilised or gel form, hyaluronic acid or derivatives thereof such as sodium hyaluronate, in crystalline form or in solution, as well as alginates may be conveniently used as carriers for magaldrate.
The compositions according to the invention can be formulated in any form convenient for topical use, in particular cream, vaginal/rectal cream, lotion, dusting powder, gel, creamgel, foams, powders for spray doser, patches, gauzes, hydrofibers, hydrocolloids, hydrogel, alginates, sponges, tissues/tablets, adhesive or non adhesive-films.
Examples of preferred combinations of the above mentioned carriers and/or ingredients include: Magaldrate + collagen;
Magaldrate + collagen + hyaluronic acid;
Magaldrate + collagen + hyaluronic acid + silver;
Magaldrate + collagen + hyaluronic acid + zinc; Magaldrate + collagen + hyaluronic acid + silver + zinc;
Magaldrate + collagen + hyaluronic acid + zinc + alginates;
Magaldrate + collagen + hyaluronic acid + zinc + alginates + silver.
Magaldrate is present in the formulations in concentrations of between
0.1% and 30% by weight, and preferably between 1% and 15% in the case of the cream or lotion formulations, while for powders, magaldrate can be present in percentages of between 0.5% and 50% by weight, and preferably between 1 % and 15%.
The properties of magaldrate can be supplemented by adding adjuvants, synergic and/or complementary substances such as vitamin E (tocopherols), vitamin A (retinol), vitamin C, alpha lipoic, camosine, zinc compounds, zinc oxide, cysteine, flavonoids, carotenoids, phytosterols, aloe, ozonized oil, alginates, amikacin or other antibiotics/anti-septics, silver compounds (e.g. colloidal silver, nanocrystalline silver, silver nitrate, silver sulphadiazine, silver acetylmethionate, silver borosilicate, silver sulfate), iodine or iodine compounds, chlorhexidine or local anaesthetics (dibucaine, benzocaine or lidocaine).
For treatments of the mucous membranes, such as the vaginal mucosa, the product can be formulated as a vaginal pessary, ointment, suspension or cream. These preparations can be manufactured by known techniques, using conventional excipients.
For example, a fatty base, one or more emulsifying agents, an aqueous phase and one or more antimicrobial agents are generally used for the cream formulation. The following ingredients are used: - Fatty substance amounting to between 5% and 70% by weight, and preferably between 10% and 40%.
- Emulsifying agent amounting to between 0% and 20% by weight, and preferably between 0.5% and 10%. - Water amounting to between 10% and 90% by weight, and preferably between 40% and 80%.
- Thickening agent amounting to between 0% and 6% by weight, and preferably between 0% and 2%.
- An antimicrobial preservative. - Chelating agents, antioxidants, and pharmaceutical form stabilisers.
"Fatty base" means a substance that is liquid or solid at ambient temperature which may be an aliphatic fatty acid ester, an aromatic acid ester, a triglyceride, a long-chain aliphatic alcohol, vaseline, lanolin or liquid paraffin.
The fatty substance used is not limited to a particular quantity but can vary, depending on the characteristics of the cream.
Anionic, cationic, non-ionic or amphoteric surfactants can be used as emulsifying agents. The non-ionic type is generally preferable because it is less irritating to the damaged skin; it may be the oxyethylenated, polyhydroxide or polymer type. The oxyethylenated type can be a derivative between an alcohol with a high molecular weight and a fatty acid, or an oxyethylenated derivative of a alkyl-phenol, an aliphatic amine, a polyvalent alcohol, etc. The polyhydroxide type can include, for example, fatty acid monoesters of glycerin, a sorbitan ester of fatty acid, an amide between a fatty acid and ethanolamine, a monoester between a fatty acid and polyoxypropylene, a monoester between a fatty acid and polyoxyethylene glycerin, and so on. Said emulsifying agents can be used separately or mixed together.
The emulsifying agent used is not restricted to a particular quantity, but can vary according to the desired characteristics of the end product. Said quantity is usually between 1 % and 20%, and preferably between 3% and 15%, by weight.
Conventional excipients are used for the lotion formulation; they basically comprise a fatty base, one or more emulsifying agents, an aqueous phase, and one or more antimicrobial agents. The following ingredients are used:
- A liquid fatty substance amounting to between 1% and 40% by weight, and preferably between 5% and 20%.
- Emulsifying agent amounting to between 0% and 20% by weight, and preferably between 0.5% and 5%. - Water amounting to between 0% and 90% by weight, and preferably between 50% and 80%.
- A thickening agent amounting to between 0% and 6% by weight, and preferably between 0.05% and 2%.
- An antimicrobial preservative. - Chelating agents, antioxidants, and pharmaceutical form stabilisers.
The dusting powder formulation is particularly indicated in cases involving formation of exudates, which are absorbed and agglomerated by the product, thus creating an effective barrier against external agents which often cause further complications.
Conventional excipients with a very fine particle size, generally < 100 microns, are used to prepare the dusting powder.
The excipients act as diluents, promote the flowability of the powder mixture, and prevent it from caking.
The following ingredients are used:
- An ingredient acting as a diluent amounting to between 30% and 99% by weight, and preferably between 75% and 95%. - Flowability promoter amounting to between 0% and 20% by weight, and preferably between 0.5% and 5%.
- Chelating agents, antioxidants, and pharmaceutical form stabilisers.
The following examples illustrate the invention in greater detail. EXAMPLE NO. 1
Cream based on 5% magaldrate for topical use
MAGALDRATE 5.0 g
CRODAMOL SSE 8.0 g
CITHROL GMS SE 5.5 g STEARIC ACID 4.O g
CRODA BASE 3.0 g
CETOMACROGOL 1000 3.0 g
ISOPROPYL MYRISTATE 2.5 g
ISOFOL 20 1.O g BUTYLHYDROXYANISOL 0.05 g
BUTYLHYDROXYTOLUENE 0.05 g
MIXTURE OF PARABENS 0.3 g
DISODIUM EDTA 0.1 g
SODIUM DEHYDROACETATE 0.1 g IMIDAZOLIDINYL UREA 0.2 g
LACTIC ACID q.s. to pH 5.5
PURIFIED WATER q.s. to 10O g EXAMPLE NO. 2
Cream based on 2.5% magaldrate + amikacin for topical use
MAGALDRATE 2.5 g
AMIKACIN 2.5 g SORBITAN MONOSTEARATE 1.5 g
ISOPROPYL MYRISTATE 5.0 g
STEARYL ALCOHOL 6.0 g
POLYSORBATE 60 2.5 g
PROPYLENE GLYCOL 20.0 g BENZOIC ACID 0.2 g
CETYL ALCOHOL 5.O g
PURIFIED WATER q.s. to 10O g EXAMPLE NO. 3
Cream based on 2% magaldrate + vit. E for topical use MAGALDRATE 2.O g
VITAMIN E ACETATE 5.0 g
POLYOXYETHYLENEGLYCOL PALMITATE-STEARATE 9.0 g
POLYOXYETHYLATED GLYCERIDES OF
■ SATURATED FATTY ACIDS 5.8 g METHYL PARABEN 0.135 g
PROPYL PARABEN 0.015 g
PURIFIED WATER q.s. to 10O g EXAMPLE NO. 4 Cream based on 10% magaldrate for vaginal use MAGALDRATE 10.O g
GLYCERYL STEARATE 5.5 g
STEARIC ACID 4.O g
CETOMACROGOL 1000 3.O g ISOPROPYL MYRISTATE 2.5 g
2-OCTYLDODECANOL 1.O g
BUTYLHYDROXYANISOL 0.05 g
BUTYLHYDROXYTOLUENE 0.05 g DISODIUM EDTA 0.1 g
METHYL PARABEN 0.200 g
PROPYL PARABEN 0.025 g
SODIUM DEHYDROACETATE 0.1 g
IMIDAZOLIDINYL UREA 0.2 g LACTIC ACID q.s. to pH 5.5
PURIFIED WATER q.s. to 10O g As regards the preparation process, Magaldrate and the other ingredients, apart from the fatty components, are dissolved or dispersed in the hot aqueous phase (70-800C). The fatty substances, heated to 65-75°C, are then added to the aqueous phase and subjected to suitable stirring (mixer).
[EXAMPLE NO. 5
Lotion based on 7.5% magaldrate
MAGALDRATE 7.5 g GLYCERIN 5.0 g
AVICEL R GEL 2.O g
CARBOXYMETHYLCELLULOSE 2.5 g
BENZALKONIUM CHLORIDE 0.50 g
PURIFIED WATER q.s. to 100 g The preparation of the pharmaceutical lotion is similar to that of the cream. EXAMPLE NO. 6
Dusting powder based on 5% magaldrate and 2% zinc oxide
MAGALDRATE 5.0 g
ZINC OXIDE 2.O g COLLOIDAL SILICON DIOXIDE 5.0 g
CORN STARCH 20.0 g
TALC 68.0 g
Preparation
The preparation involves simply mixing the ingredients. However, this operation must be conducted under conditions that guarantee the sterility of the product.
EXAMPLE NO. 7
Cream based on magaldrate 1% and collagene 5%
COMPONENTS: % (P/P)
EMULGIN BA 25 3
LANETTE O OR 6
LANETTE 22 4
EMULGIN SG 0.5
MYRITOL 331 1
CETIOL CC 8
DIMETICONE 0.5
BHA 0.05
BHT 0.05
PARABENS MNIXTURE 0.3
IMIDAZOLIDINYL UREA 0.2
DISODIUM EDTA 0.1
SODIUM DEHYDROACETATE 0.1
NATIVE COLLAGEN TYPE I 1 % GEL 5 MAGALDRATE 1
LACTIC ACID q.s. to PH=5.5
WATER q.s. to 100% EXAMPLE NO. 8
Cream based on magaldrate 3% and collagen 5%
COMPONENTS: % (P/P)
EMULGIN BA 25 3
LANETTE O OR 6
LANETTE 22 4
EMULGIN SG 0.5
MYRITOL 331 1
CETIOL CC 8
DIMETICONE 0.5
BHA 0.05
BHT 0.05
PARABENS MNIXTURE 0.3
IMIDAZOLIDINYL UREA 0.2
DISODIUM EDTA 0.1
SODIUM DEHYDROACETATE 0.1
NATIVE COLLAGEN TYPE I 1 % GEL 5
MAGALDRATE 3
LACTIC ACID q.s. to PH=5.5
WATER q.s. to 100%
EXAMPLE NO. 9 Cream based on magaldrate 5% and collagene 5%
COMPONENTS: % (P/P)
EMULGIN BA 25 3
LANETTE O OR COGNIS 6 LANETTE 22 4
EMULGIN SG 0.5
MYRITOL 331 1
CETIOL CC 8 DIMETICONE 0.5
BHA 0.05
BHT 0.05
PARABENS MNIXTURE 0.3
IMIDAZOLIDINYL UREA 0.2 DISODIUM EDTAAGRAR 0.1
SODIUM DEHYDROACETATE AGRAR 0.1
NATIVE COLLAGEN TYPE I 1 % GEL 5
MAGALDRATE 5
LACTIC ACID q.s. to PH=5.5 WATER q.s. to 100%
Preparation
The lipohilic phase is heated to 70-750C1 stirring with a mixer to obtain melting/homegeneization of the components. Part of water is added with stirring, keeping the above temperature. Temperature is then lowered to T<40°C, the hydrophilic components are dissolved/dispersed the powders in water, then added with stirring to complete homogeization. Finally pH is adjusted with lactic acid.

Claims

1. Topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.
2. Compositions as claimed in claim 1 , in the form of a cream, lotion, dusting powder, pessary or suppository, gel, creamgel, foams, powders for spray doser, patches, gauzes, hydrofibers, hydrocolloids, hydrogel, alginates, sponges, tissues/tablets, adhesive or non adhesive-films.
3. Compositions as claimed in claim 1 or 2, also containing vitamin E, vitamin A, vitamin C, zinc compounds, zinc oxide, cysteine, silver compounds, alpha-lipoic acid, camosine, ozonized oil, alginates, phytosterols, flavonoids, carotenoids, aloe, Chitosan, iodine and iodine compounds, chlorhexidine, antibiotics, anti-septics, local anaesthetics.
4. Use of magaldrate for the preparation of topical medicinal products for the treatment of ulcers, venous ulcers, superficial ulcers, wounds, burns, eczema, rashes, psoriasis, cutaneous lesions, diabetic lesions, traumatic lesions, surgical wounds, abrasions, dermatitis, macerations, stoma skin complications, inflammatory and/or infective skin disorders.
PCT/IB2008/002047 2007-03-29 2008-03-28 Topical compositions containing magaldrate Ceased WO2008142569A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/593,299 US8617618B2 (en) 2007-03-29 2008-03-28 Topical compositions containing magaldrate
EP08789004.2A EP2139451B1 (en) 2007-03-29 2008-03-28 Topical compositions containing magaldrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000644A ITMI20070644A1 (en) 2007-03-29 2007-03-29 TOPIC COMPOSITIONS INCLUDING MAGALDRATE
ITMI2007A644 2007-03-29

Publications (2)

Publication Number Publication Date
WO2008142569A2 true WO2008142569A2 (en) 2008-11-27
WO2008142569A3 WO2008142569A3 (en) 2009-06-04

Family

ID=40032237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002047 Ceased WO2008142569A2 (en) 2007-03-29 2008-03-28 Topical compositions containing magaldrate

Country Status (4)

Country Link
US (1) US8617618B2 (en)
EP (1) EP2139451B1 (en)
IT (1) ITMI20070644A1 (en)
WO (1) WO2008142569A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011237638B2 (en) * 2010-04-09 2016-05-05 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10786595B2 (en) 2011-03-24 2020-09-29 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10792337B2 (en) 2013-03-15 2020-10-06 Kci Licensing, Inc. Wound healing compositions

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125892B2 (en) * 2014-02-03 2015-09-08 George D. Petito Composition for reduced scar formation of wounds
RU2693228C2 (en) * 2017-02-08 2019-07-02 Общество с ограниченной ответственностью "ЛЕРАН" (ООО "ЛЕРАН") Composite for accelerated healing of wounds of various aetiologies, use of composite as cosmetic agent and as a therapeutic agent in veterinary science, agent for skin regeneration based on composite
US20180289836A1 (en) * 2017-04-05 2018-10-11 Drexel University Complexes and methods of reducing inflammation
CN110286009B (en) * 2019-06-06 2021-09-24 强安医疗器械有限公司 Rectal mucosa exfoliated cell sample pretreatment liquid and preparation method thereof
CN112190541A (en) * 2020-09-27 2021-01-08 安婕妤化妆品科技股份有限公司 Privacy care gel product
CN114533668A (en) * 2022-03-25 2022-05-27 辽宁大熊制药有限公司 Method for improving antibacterial effect of drug for neutralizing gastric acid

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58636B1 (en) 1984-10-17 1993-10-20 American Home Prod Fluidized and rehydratable magaldrate compositions
GR862366B (en) 1985-10-08 1987-01-19 American Home Prod Exogenously acidified antacid compositions having cytoprotective properties
WO2006103702A2 (en) * 2005-04-01 2006-10-05 Mccullough Ricky W Enhanced bio-adherent polymeric compositions for coating mucosal and epidermal epithelium

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011237638B2 (en) * 2010-04-09 2016-05-05 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US9999702B2 (en) 2010-04-09 2018-06-19 Kci Licensing Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US11090409B2 (en) 2010-04-09 2021-08-17 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US11896733B2 (en) 2010-04-09 2024-02-13 3M Innovative Properties Company Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10786595B2 (en) 2011-03-24 2020-09-29 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
US10792337B2 (en) 2013-03-15 2020-10-06 Kci Licensing, Inc. Wound healing compositions

Also Published As

Publication number Publication date
US20100092577A1 (en) 2010-04-15
US8617618B2 (en) 2013-12-31
ITMI20070644A1 (en) 2008-09-30
EP2139451B1 (en) 2017-07-05
EP2139451A2 (en) 2010-01-06
WO2008142569A3 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
EP2139451B1 (en) Topical compositions containing magaldrate
JP3583166B2 (en) Powder preparation for damaged skin repair
CN102711729B (en) Topical gels
JP7568185B2 (en) Uses of amino acid-based nutrients and pharmaceutical compositions containing same
WO1998022114A1 (en) A method for promoting tissue repair
CN1300215A (en) Preventives/remedies for skin diseases
WO2008037262A1 (en) Wound healing composition comprising phosphate, iron and copper
AU2007278428B2 (en) Use of polyethylene glycol in inflammatory skin conditions and wound healing
CN101972225A (en) Pirfenidone-contained gel composition
US20140348873A1 (en) Urea-Silicone Gel for Hyperkeratosis Treatment
US20080058283A1 (en) Composition based on salts of hyaluronic acid for treating epithelial lesions
RU2096031C1 (en) Medicinal substance for prophylaxis and treatment of inflammatory diseases of parodontium tissues
WO2024239066A1 (en) Pharmaceutical composition
Semkina Ointments, gels, liniments, and creams containing phytopreparations (a review)
US11291673B2 (en) Topical doxycycline hydrogel with improved long-term stability
WO2010075314A2 (en) Topical formulations of flap inhibitors for the treatment of dermatological conditions
CN112438942A (en) Pharmaceutical composition containing alkalizer and its synergist and its application
RU2124354C1 (en) &#34;emparcrol&#34; - as a wound-healing agent
ES2235443T3 (en) TOPIC PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS, WHICH ARE OF BORNEOL AND BISMUTO SUBGALATE.
CN112439066A (en) Pharmaceutical composition comprising chemical ablation agent and pH adjusting agent and use thereof
EA018384B1 (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate
US20150182630A1 (en) Hydrogel composition for the treatment of dermatological disorders
TW202535906A (en) New short-chain peptides and derivatives thereof
CN120859934A (en) Topical composition containing sulfur-containing sugar-aluminum wet gel
WO2017105207A1 (en) Pharmaceutical composition for treating skin ulcers, injuries and burns

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
REEP Request for entry into the european phase

Ref document number: 2008789004

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008789004

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08789004

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12593299

Country of ref document: US